Literature DB >> 9269826

The clinicopathological characteristics of gonadotroph cell adenoma: a study of 118 cases.

D M Ho1, C Y Hsu, L T Ting, H Chiang.   

Abstract

Gonadotroph cell adenoma was the most common pituitary adenoma, constituting 35% of the pituitary adenomas in our series of 339 patients with surgically removed pituitary adenomas from June 1987 to December 1995. The average age of these patients was 53 years, with a male predominance (1.5:1). The most common neurological symptoms were visual symptoms and headache. Amenorrhea and galactorrhea were recorded in 41% and 14%, respectively, of the female patients of reproductive age. Oncocytic change of varying degrees was seen in 69% of the tumors, and the average age of these patients (56 years) was older than those who had no such change (47 years) (P < .005). Five types of gonadotroph cell adenomas were recognized; they were tumors that contained (1) betaFSH, betaLH, and alphaSU, (2) betaFSH and betaLH, (3) betaFSH and alphaSU, (4) betaFSH, and (5) alphaSU. The immunostaining of betaFSH-containing cells was usually diffuse, whereas staining of betaLH- or alphaSU-containing cells was usually focal. Double immunostaining showed the immunoreactive cells containing one or any combination of the gonadotropin subunits. Increases in serum gonadotropin levels were only seen in 35% of the patients with gonadotroph cell adenoma. There was no correlation between serum hormonal levels and immunostaining results. Of the 33 recurrent cases, significant decrease or total absence of immunoreactivity of one or more hormone subunits in subsequent biopsy specimens were seen in three cases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9269826     DOI: 10.1016/s0046-8177(97)90005-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  15 in total

Review 1.  Neurology of the pituitary gland.

Authors:  J R Anderson; N Antoun; N Burnet; K Chatterjee; O Edwards; J D Pickard; N Sarkies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

2.  Aggressive giant pituitary adenoma presenting as a nasopharyngeal mass: magnetic resonance imaging and pathologic findings.

Authors:  T P Ravichandran; R Bakshi; R R Heffner; K J Gibbons; V E Bates; D J Durante; W R Kinkel
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

Review 3.  Functional Gonadotroph Adenomas: Case Series and Report of Literature.

Authors:  David J Cote; Timothy R Smith; Courtney N Sandler; Tina Gupta; Tejus A Bale; Wenya Linda Bi; Ian F Dunn; Umberto De Girolami; Whitney W Woodmansee; Ursula B Kaiser; Edward R Laws
Journal:  Neurosurgery       Date:  2016-12       Impact factor: 4.654

Review 4.  Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.

Authors:  Mansur E Shomali; Laurence Katznelson
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 5.  Silent (clinically nonfunctioning) pituitary adenomas.

Authors:  Sarah E Mayson; Peter J Snyder
Journal:  J Neurooncol       Date:  2014-03-28       Impact factor: 4.130

6.  Expression pattern of neuronal intermediate filament α-internexin in anterior pituitary gland and related tumors.

Authors:  D Schult; A Hölsken; M Buchfelder; S-M Schlaffer; S Siegel; I Kreitschmann-Andermahr; R Fahlbusch; R Buslei
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

7.  A silent follicle-stimulating hormone-producing pituitary adenoma in a teenage male.

Authors:  Hiroyuki Tamiya; Noriaki Fukuhara; Naohiro Yoshida; Hisanori Suzuki; Akira Takeshita; Naoko Inoshita; Hiroshi Nishioka; Yasuhiro Takeuchi; Toshiaki Sano; Shozo Yamada
Journal:  Endocr Pathol       Date:  2011-12       Impact factor: 3.943

Review 8.  Serum tumor markers in the evaluation of male germ cell tumors.

Authors:  LaMont J Barlow; Gina M Badalato; James M McKiernan
Journal:  Nat Rev Urol       Date:  2010-11       Impact factor: 14.432

9.  ASSESSMENT AND COMPARISON OF HORMONAL IMMUNOEXPRESSION AND THE CLINICAL PICTURE IN PATIENTS WITH PITUITARY ADENOMAS.

Authors:  B Kwinta; A Myszka; R M Krzyżewski; K M Kliś; M R Dragan; D Adamek
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

10.  Nuclear accumulation of basic fibroblast growth factor as a predictor for the recurrence of pituitary adenomas.

Authors:  Shinji Fukui; Naoki Otani; Hiroshi Nawashiro; Akiko Yano; Takahito Miyazawa; Akira Ohnuki; Nobusuke Tsuzuki; Hiroshi Katoh; Shoichiro Ishihara; Takamoto Suzuki; Katsuji Shima
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.